Go Deep
Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | -17,710 | -1.9 | -1.36 | -0.38 | 176.18 |
| Oct 2026 | -17,710 | -1.9 | -1.36 | -0.38 | 175.65 |
| Oct 2026 | -17,751 | -1.9 | -1.39 | -0.38 | 179.48 |
| Oct 2026 | -17,710 | -1.9 | -1.36 | -0.38 | 175.22 |
| Oct 2026 | -17,731 | -1.9 | -1.37 | -0.38 | 177.31 |
| Oct 2026 | -17,874 | -2.1 | -1.47 | -0.38 | 190.58 |
| Oct 2026 | -17,905 | -2.1 | -1.50 | -0.38 | 192.95 |
| Oct 2026 | -17,874 | -2.1 | -1.47 | -0.38 | 189.73 |
Foghorn Therapeutics Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 16,072,000.0 | 3,267,000.0 | 9,247,000.0 | 8,153,000.0 |
| Net Profit | -7,191,000.0 | -19,875,000.0 | -21,664,000.0 | -15,849,000.0 |
| EPS | -0.1 | -0.3 | — | -0.2 |
Foghorn Therapeutics Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 30,909,000.0 | 22,602,000.0 | 34,155,000.0 | 19,228,000.0 | — |
| Net Profit | -74,283,000.0 | -86,620,000.0 | -98,426,000.0 | -108,882,000.0 | — |
| EPS | -1.2 | -1.6 | -2.3 | -2.6 | — |
Foghorn Therapeutics Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 198,103,000.0 | 283,982,000.0 | 285,916,000.0 | 404,883,000.0 | — |
| Total Liabilities | 306,603,000.0 | 329,510,000.0 | 363,106,000.0 | 404,771,000.0 | — |
| Total Equity | -108,500,000.0 | -45,528,000.0 | -77,190,000.0 | 112,000.0 | — |
Owes vs Owns
Foghorn Therapeutics Inc. owed $1.40 for every $1 it owned in Jun 2026, up from $1.00 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 1.40× | 1.55× | 1.16× | 1.27× | 1.00× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Foghorn Therapeutics Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 80.2%Fixed assets (tangible) 16.6%Other assets 3.2%
How it's funded — Dec 2025
Long-term debt 13.2%Payables 1.4%Other liabilities 85.1%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 158.9 | 243.7 | 234.1 | 345.8 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 32.9 | 32.6 | 42.9 | 49.4 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 6.3 | 7.6 | 8.9 | 9.7 |
| Liabilities & equity | ||||
| Short-term debt | 0.9 | 9.1 | 8.5 | 6.0 |
| Long-term debt | 40.3 | 28.1 | 36.6 | 45.5 |
| Payables | 4.3 | 3.8 | 6.3 | 5.4 |
| Other liabilities | 261.1 | 288.6 | 311.8 | 347.9 |
| Shareholders' equity | -108.5 | -45.5 | -77.2 | 0.1 |
| Net tangible assets | -108.5 | -45.5 | -77.2 | 0.1 |
Foghorn Therapeutics Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -86,099,000.0 | -100,406,000.0 | -118,106,000.0 | 193,612,000.0 | — |
| Investing Activities | 112,040,000.0 | -29,904,000.0 | 144,450,000.0 | -244,322,000.0 | — |
| Financing Activities | 1,023,000.0 | 105,428,000.0 | 1,778,000.0 | 1,763,000.0 | — |